:

DEEPSEEK POSTS $106M LOSS ON $70.7M REVENUE

INDUSTRY DESK1 MIN READ
WED, AUG 26, 2026

■ AI-SUMMARIZED FROM 1 SOURCE ▸ TIMELINE

DeepSeek generated $70.7 million in revenue during the first seven months of 2026 while posting a $106 million net loss, according to sources cited by The Information. The figures represent roughly 10x the Chinese AI startup's full-year 2025 revenue.

DeepSeek's 2026 performance shows significant revenue growth alongside mounting losses. The startup generated approximately 475 million yuan ($70.7 million) in the first seven months of this year, compared to roughly $7 million in full-year 2025 revenue. However, the company's net loss expanded to $106 million for the seven-month period, compared to a $139 million net loss for all of 2025. The loss reduction relative to full-year figures suggests improved unit economics or cost management. DeepSeek has emerged as a notable competitor in the AI space, attracting significant attention and investment. The company's financial trajectory reflects the capital-intensive nature of AI development, where substantial losses during growth phases are common as companies invest in model training, infrastructure, and market expansion.

■ SOURCES

Techmeme

■ SUMMARY WRITTEN BY AI FROM THE LINKS ABOVE

■ MORE FROM THE AI DESK

Despite early predictions that AI would eliminate radiologist jobs, the technology is instead transforming the role. Radiologists are evolving from image interpreters to clinical decision-makers working alongside AI systems.

JUST NOWAI Desk

Bill Gates says the artificial intelligence era represents one of history's most disruptive periods and that governments and institutions are unprepared. He is calling for a regulatory framework to manage the transition.

JUST NOWAI Desk

A Pew Research Center survey found that 28% of Americans turn to AI chatbots for quick health information, with most users finding the results helpful. The trend reflects growing reliance on artificial intelligence for medical guidance.

1H AGOAI Desk

Niu Zhangming, founder and CEO of AI biotech firm Mindrank AI, detailed the company's business strategy and approach to artificial intelligence in pharmaceutical development at the Asia Innovation and Technology Enterprises Going Global Summit in Hong Kong.

4H AGOAI Desk

■ SUBSCRIBE TO THE DAILY BRIEF

ONE EMAIL, 5 STORIES, 06:00 UTC. UNSUBSCRIBE ANYTIME.